Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment
Pharmaceutics · 10.02.2025 · 17 (2) · 224
DOI: 10.3390/pharmaceutics17020224 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 10.02.2025. Verfasst von Ji Su Park und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Acquisition Program Administration and Ministry of Trade, Industry and Energy of Korean government, Ministry of Education, Institute of Civil Military Technology Cooperation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease marked by vascular remodeling, inflammation, and smooth muscle cell proliferation, with limited treatment options focused primarily on symptom management. The multifactorial nature of PAH, encompassing genetic, autoimmune, and connective tissue contributions, complicates its treatment, while irreversible vascular changes, such as fibrosis, remain unaddressed by current therapies. Fundamental research on molecular pathways and targeted delivery systems has paved the way for advanced therapeutic strategies that aim to modify disease progression rather than merely manage symptoms. Nanoparticle-based drug delivery systems, leveraging controlled release and pulmonary targeting, offer a promising avenue to overcome these challenges. Such systems enable precise localization to pulmonary vasculature, minimize systemic side effects, and support emerging approaches like gene therapy and combination treatments. Future research should focus on refining nanoparticle formulations for personalized medicine, optimizing inhalation delivery systems, and integrating multi-target approaches to achieve curative outcomes in PAH. This review explores pathophysiology of PAH, current pharmacological strategies, and innovative nanoparticle-based therapies, emphasizing their potential to transform PAH treatment and address its underlying mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea.
- Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of Korea.
ORCID-Profile: Gayong Shim
Förderung
- Defense Acquisition Program Administration and Ministry of Trade, Industry and Energy of Korean government
- Ministry of Education
- Institute of Civil Military Technology Cooperation
- Basic Science Research Program through the National Research Foundation of Korea
Zitieren
APA
Park, J. S., Choi, Y. H., Min, J. Y., Lee, J., & Shim, G. (2025). Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment. Pharmaceutics, 17(2), 224. https://doi.org/10.3390/pharmaceutics17020224
Vancouver
Park JS, Choi YH, Min JY, Lee J, Shim G. Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment. Pharmaceutics. 2025;17(2):224. doi:10.3390/pharmaceutics17020224
BibTeX
@article{Park2025,
author = {Park, Ji Su and Choi, Yong Hwan and Min, Ji-Young and Lee, Jaeseong and Shim, Gayong},
title = {Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {2},
pages = {224},
doi = {10.3390/pharmaceutics17020224}
}
EUVIMED